Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Merck & Co.'s Enflonsia (clesrovimab) receives EU approval for infant respiratory syncytial virus lower respiratory tract disease prevention
Antibody, infectious disease, monoclonal antibody, RSV, infant population - Read more

Samsung Bioepis' OBODENCE (denosumab) shows consistent Ph3 efficacy across osteoporosis patient subgroups
Protein therapy, metabolic, biosimilar, osteoporosis, denosumab, RANK ligand inhibitor - Read more

Monopar Therapeutics' ALXN1840 (tiomolibdate choline) shows greater neurologic benefit vs standard of care in Ph3 Wilson disease trial
Small molecule, neurological, Wilson disease, copper chelation, metabolic disorder - Read more

Merck & Co. unveils Ph1/Ph2 data for MK-2010 (MK-2010), PD-1xVEGF bispecific, in non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1, VEGF - Read more

Novo Nordisk's (semaglutide) shows better lean mass preservation over Eli Lilly's (tirzepatide) in observational body composition study
Small molecule, metabolic, GLP-1 agonist, obesity, body composition, semaglutide - Read more

Kura Oncology's darlifarnib (KO-2806) shows 44% response rate in Ph1 clear cell renal cell carcinoma cabozantinib-pretreated patients
Small molecule, cancer, renal cell carcinoma, farnesyl transferase inhibitor, VEGFR inhibitor, combination therapy - Read more

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

Former Genentech leader unveils Synthetic Design Lab, developing adaptive "smart" ADC cancer drugs
Antibody-drug conjugate, oncology strategic - Read more

Orthogon Therapeutics raises additional $11M, advancing polyomavirus-focused drug discovery platform
Infectious disease, small molecule, antiviral, transplant, platform technology - Read more

Biovac Institute raises $108M to expand Cape Town vaccine facility, targeting 400M doses
Vaccine, infectious disease, major transaction, operational - Read more

Teva wins appeal reinstating $177M patent infringement verdict against Eli Lilly over migraine drugs
Monoclonal antibody, neurological, competitive, revenue impact - Read more

UCB to acquire Neurona Therapeutics for up to $1.2B, expanding into seizure cell therapy
Cell therapy, epilepsy, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA marks first-year progress on animal testing roadmap, but experts warn full transition remains years away
New approach methodologies, preclinical safety, regulatory, operational, strategic - Read more

RFK Jr. defends FDA's Makary, backs Replimune RP1 rejection, claims pharma controls congress and media
Oncolytic immunotherapy, oncology, regulatory, competitive - Read more

FDA vet Pazdur warns of political influence, staff anxiety, and eroding regulatory firewall at agency
Regulatory oversight, oncology, operational, political influence - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here